Global collaboration action towards better prevention, treatment and clinical management of HIV co-infections or co-morbidities in sub-Saharan Africa

Overview

Funding for late-stage clinical research aimed at improving prevention, treatment, and clinical management of HIV co-infections or co-morbidities in sub-Saharan Africa. Targets consortia with strong representation from sub-Saharan African institutions and international collaborators to generate evidence for public health decision-making.

Who Can Apply

Consortia must include:

• At least three independent legal entities from different eligible countries.
• At least one entity from an EU Member State or Horizon Europe-associated country that is also an EDCTP Association member.
• At least one entity from a sub-Saharan African country that is an EDCTP Association member.

Contributing partners (countries, international organisations, or public/private entities) must provide in-kind or financial contributions, with endorsement letters submitted before the second-stage deadline.

Funding Details

• Maximum grant amount: 10,000,000 EUR.
• Contributing partners must leverage financial and/or in-kind contributions equal to or greater than the requested funding.

What Is Funded

• Late-stage clinical development (phase IIb and beyond) of novel or improved products for HIV co-infections or co-morbidities, excluding tuberculosis.
• Integration of healthcare services and support programs for HIV co-infections/co-morbidities in sub-Saharan African healthcare systems.
• Cost-effectiveness and implementation research, particularly for long-acting injectables and monoclonal antibodies.
• Activities supporting safer polypharmacy use and public health policy development.
• Preclinical preparatory work (e.g., protocol development, lab test evaluation) if enabling clinical studies.

Technology / Maturity Requirements

• Focus on late-stage clinical development (phase IIb and beyond).
• Preclinical studies are excluded unless directly enabling clinical research.

Key Dates

• Open date: 2026-01-13T23:00:00.000000Z.
• Deadline: 2026-03-03T23:00:00.000000Z.

Application Process (High-Level)

• Two-stage process:

1. First-stage submission (no anonymisation required). 2. Second-stage submission for selected proposals, including endorsement letters from contributing partners.

Post-Award Obligations

• Submission of a Plan for the Exploitation and Dissemination of Results, including an access plan for affordable, available, and accessible health technologies.
• Annual reporting on product development and exploitation status for up to four years post-project.
• Non-exclusive licensing may be required if results are not exploited within one year of project completion.

Geographic Scope & Language

• Eligible countries: EU Member States, Horizon Europe-associated countries, EDCTP Association members in sub-Saharan Africa, and other countries if participation is deemed essential.
• Application language: English.

Notes

• Proposals must demonstrate meaningful contributions from sub-Saharan African institutions and may include vulnerable populations.
• Collaboration with African manufacturers and engagement with regulators is encouraged.
• Excludes research focused solely on HIV prevention/treatment or standalone epidemiological/surveillance studies.